Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover study of PT005 versus placebo and Foradil Aerolizer in COPD
ACTRN12609000191291Phase 2Completed
- Sponsor
- Pearl Therapeutics
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of formoterol fumarate MDI in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Pearl Therapeutics. Primary endpoint: Change in FEV1 AUC(0-12) from baseline. Started Oct 2008; status: completed.
02
Drugs
formoterol fumarate MDI
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12609000191291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000191291.